BeOne Medicines (ONC) Total Non-Current Liabilities (2015 - 2026)

BeOne Medicines (ONC) has reported Total Non-Current Liabilities for 12 consecutive years, with $2.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 453.09% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (up 453.09% YoY), while the FY2025 annual figure was $2.0 billion, up 434.67% from the prior year.
• Total Non-Current Liabilities slipped to $2.0 billion in Q1 2026 per ONC's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $2.0 billion in Q4 2025 and bottomed at $318.1 million in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $705.7 million across 5 years, with a median of $525.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 34.35% — and 2026, when it surged 453.09%.
• BeOne Medicines' Total Non-Current Liabilities stood at $527.4 million in 2022, then slipped by 13.19% to $457.8 million in 2023, then decreased by 18.36% to $373.8 million in 2024, then surged by 434.67% to $2.0 billion in 2025, then decreased by 0.84% to $2.0 billion in 2026.
• Business Quant data shows ONC's Total Non-Current Liabilities at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.1 billion in Q3 2025.